Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2022-04-07 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司关于终止2021年度非公开发行股票事项的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the termination of a planned non-public issuance of A shares by the company. It details the board and supervisory meetings, decisions made, and the reasons for termination. It does not contain financial statements or detailed financial data but rather informs shareholders and the public about the cessation of a capital raising activity. This fits the category of a Capital/Financing Update (CAP) as it relates to changes in the company's financing plans and capital structure.
2022-04-07 Chinese
金宇生物技术股份有限公司独立董事关于终止非公开发行股票事项涉及关联交易的事前认可意见
Regulatory Filings
2022-04-07 Chinese
金宇生物技术股份有限公司第十届董事会第十五次会议决议公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of the company, including decisions on terminating a private placement, signing termination agreements, and approving a share repurchase plan. It includes voting results, authorization details, and references to related announcements on the stock exchange website. The document does not contain financial statements or comprehensive financial data but rather reports on board decisions and corporate actions. The main focus is on the approval of a share repurchase plan, which is a transaction involving the company's own shares. Therefore, the document fits best under the category of 'Transaction in Own Shares' (POS). The document length is about 3013 characters, which is consistent with a detailed announcement rather than a full report.
2022-04-07 Chinese
金宇生物技术股份有限公司关于对外捐赠的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding a charitable donation to support COVID-19 pandemic control efforts. It includes details about the donation items and amounts, the company's social responsibility stance, and confirms no significant impact on company performance. There is no financial data, no mention of financial results, no regulatory filings or certifications, no meeting materials, no voting results, no capital changes, no legal proceedings, and no merger or acquisition activity. The document is a regulatory announcement about a corporate social responsibility action, which does not fit into financial report categories. Therefore, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2022-03-01 Chinese
金宇生物技术股份有限公司关于子公司获得兽药产品批准文号批件的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a subsidiary obtaining an official approval number for a veterinary drug product. It details regulatory approval, product specifications, and the impact on the company. There is no financial data, no mention of a report or meeting, and it is not a regulatory filing about compliance or certification. It is an announcement about a product approval, which does not fit into financial reports, management changes, or shareholder voting results. The closest fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-02-24 Chinese
金宇生物技术股份有限公司关于子公司取得新兽药注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its subsidiary obtaining a new veterinary drug registration certificate. It details the product, its development, regulatory approval, and expected impact on the company. There are no financial statements, no mention of annual or quarterly reports, no earnings data, no management or board changes, no voting results, no merger or acquisition activity, and no legal proceedings. The document is a regulatory announcement about a new product approval, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories and is a formal disclosure to the market.
2022-02-23 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.